Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals

The advent of direct antiviral agents (DAAs) has radically changed the natural history of hepatitis C virus (HCV) chronic liver disease. Even patients with cirrhosis may display improvements in liver function or features of portal hypertension following viral eradication. The aim of this study was t...

Full description

Bibliographic Details
Main Authors:	Angelo Armandi, Chiara Rosso, Giulia Troshina, Nuria Pérez Diaz Del Campo, Chiara Marinoni, Aurora Nicolosi, Gian Paolo Caviglia, Giorgio Maria Saracco, Elisabetta Bugianesi, Alessia Ciancio
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Biology
Subjects:	hepatitis C virus direct antiviral agents hepatic fibrosis liver stiffness portal hypertension cirrhosis
Online Access:	https://www.mdpi.com/2079-7737/11/8/1160

Similar Items

PARTIAL PORTOSYSTEMIC SHUNTING BY CARBON-COATED ePTFE GRAFTS FOR PORTAL HYPERTENSION IN CIRRHOTIC PATIENTS
by: I. A. Porshennikov, et al.
Published: (2010-06-01)

Diagnostic Value of Doppler Ultrasonography in Non-invasive Diagnosis of Chronic Liver Disease and Portal Hypertension
by: Manik Mahajan, et al.
Published: (2016-10-01)

Innovative angiography: a new approach to discover more hepatic vein collaterals in patients with cirrhotic portal hypertension
by: Bowen Liu, et al.
Published: (2023-05-01)

Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
by: Angelo Armandi, et al.
Published: (2021-03-01)

Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study
by: Reiner Wiest, et al.
Published: (2021-06-01)

Splenic Transcriptome Profiling of the Patients with Post-Hepatitis B Liver Cirrhosis and Portal Hypertension
by: Lingxiang Yu, et al.
Published: (2016-09-01)

Long-term efficacy and safety of anticoagulant for cavernous transformation of the portal vein cirrhotic patient with extrahepatic portal vein obstruction
by: Yongjie Zhou, et al.
Published: (2023-01-01)

Portal hypertensive colopathy in Egyptian cirrhotic patients: an endoscopic study
by: Helmy Shalaby, et al.
Published: (2018-01-01)

Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
by: Antonella Olivero, et al.
Published: (2022-03-01)

Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management
by: Francesco Santopaolo, et al.
Published: (2022-08-01)

Protein S for Portal Vein Thrombosis in Cirrhotic Patients Waiting for Liver Transplantation
by: Hao-Chien Hung, et al.
Published: (2020-04-01)

Hepatic function predictive value of hepatic venous waveform versus portal vein velocity in liver cirrhosis
by: Chidiogo Chukwunweike Onwuka, et al.
Published: (2022-01-01)

Non-cirrhotic portal fibrosis
by: Venkatesan Mukta, et al.
Published: (2014-01-01)

Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension
by: Tian Ningqiang, et al.
Published: (2012-11-01)

Liver stiffness measurement in cirrhotic patient — Implications of disease activity and treatment efficacy
by: Huang-Wei Xu, et al.
Published: (2012-12-01)

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
by: Yu Jun Wong, et al.
Published: (2023-01-01)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats
by: Meritxell Perramón, et al.
Published: (2024-02-01)

Profiles of Clinical and Liver Function Test of Hepatitis B and C Patients with Liver Cirrhosis
by: Andreas Novaldi Watang, et al.
Published: (2023-01-01)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
by: Wolfgang Kreisel, et al.
Published: (2020-08-01)

Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis
by: Yanglan He, et al.
Published: (2021-06-01)

Portal vein embolization following arterial portography for the management of an active portal bleeding after blunt liver trauma in a cirrhotic patient
by: Romain L’Huillier, et al.
Published: (2024-01-01)

Hepatic sarcoidosis with symptomatic portal hypertension: A report of 12 cases with review of the literature
by: Maxime Fauter, et al.
Published: (2022-12-01)

Non Cirrhotic Portal Vein Thrombosis: Diagnostic and Therapeutic Challenge
by: Syifa Mustika, et al.
Published: (2021-05-01)

Correlation Of Portal Vein Pulsatility Pattern And Severity Of Liver Disease In Patients With Cirrhosis And Portal Hypertension
by: Anish Subedee, et al.
Published: (2013-02-01)

Is serum apelin related to portal hemodynamics in patients with liver cirrhosis?
by: Ashraf G Dala, et al.
Published: (2018-01-01)

Diagnostic validity of serum YKL-40 as a non-invasive diagnostic marker of oesophageal varices in cirrhotic hepatitis C virus patients
by: Abdelfattah Hanno, et al.
Published: (2022-08-01)

Thrombosis of the Portal Venous System in Cirrhotic vs. Non-Cirrhotic Patients
by: Vania Cruz-Ramón, et al.
Published: (2018-05-01)

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension
by: Nikolaj Worm Ørntoft, et al.
Published: (2021-06-01)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
by: Simona Parisse, et al.
Published: (2023-10-01)

Doppler ultrasound in liver cirrhosis: correlation of hepatic artery and portal vein measurements with model for end-stage liver disease score in Egypt
by: Ahmed Abdelrahman Mohamed Baz, et al.
Published: (2020-11-01)

Characteristics of gastric microbiota in cirrhotic patients with portal hypertension
by: MU Zhiyong, et al.
Published: (2022-08-01)

Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease
by: Angelo Armandi, et al.
Published: (2023-03-01)

Phenomenology of delirium in decompensated liver disease patients-a prospective observational study
by: B Lakshmi Dorai, et al.
Published: (2021-10-01)

Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report
by: Montserrat Fraga, et al.
Published: (2019-05-01)

Transjugular intrahepatic portal shunt in the treatment of portal hypertension due to cirrhosis: single center experience
by: Yun Chen, et al.
Published: (2019-12-01)

The Importance of Liver-Fatty Acid Binding Protein in Diagnosis of Liver Damage in Patients with Acute Hepatitis
by: Ozlem Ozer Cakir, et al.
Published: (2017-04-01)

Colonic mucosal changes in Egyptian patients with liver cirrhosis and portal hypertension
by: Zakaria A Salama, et al.
Published: (2013-01-01)

Aspects of pathogenetic pharmacotherapy for portal hypertension in liver cirrhosis
by: D V Garbuzenko
Published: (2016-02-01)

Assessment of Portal Venous and Hepatic Artery Haemodynamic Variation in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients
by: Padhmini Balasubramanian, et al.
Published: (2016-08-01)

THE IMPACT OF THE SURGICAL DECISION IN THE CLINICAL EVOLUTION OF THE CIRRHOTIC PATIENT OPERATED FOR PORTAL HYPERTENSION (A REVIEW)
by: Vladimir Cazacov, et al.
Published: (2019-12-01)